Versor Investments’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Versor Investments’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-56,656	Closed	-$7.47M	–	978
2025 Q1	$7.47M	Buy	+56,656	New	+$7.06M	1.22%	2
2024 Q4	–	Sell	-3,509	Closed	-$257K	–	1020
2024 Q3	$257K	Buy	+3,509	New	+$264K	0.04%	642
2022 Q4	–	Sell	-23,435	Closed	-$1.09M	–	1024
2022 Q3	$1.09M	Buy	23,435 +7,951	+51%	+$415K	0.06%	201
2022 Q2	$884K	Buy	+15,484	New	+$878K	0.03%	285

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Versor Investments's ITCI Position: Q2 2025 in Review

Versor Investments sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 56,656 shares — an estimated $7.47M sold.

Versor Investments first reported a position in ITCI in Q2 2022 and held it in 4 quarters. The position peaked at $7.47M in Q1 2025. 3 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Versor Investments reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Versor Investments sold 56,656 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $7.47M.
Versor Investments first reported a position in Intra-Cellular Therapies Inc. in Q2 2022 and held it in 4 quarters.
Versor Investments's Intra-Cellular Therapies Inc. position peaked at $7.47M in Q1 2025.
3 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Versor Investments's 13F filing for Q2 2025, filed 5 Aug 2025.